UBS analyst Danielle Antalffy raised the firm’s price target on Zimmer Biomet (ZBH) to $96 from $91 and keeps a Sell rating on the shares. Zimmer Biomet reported a beat and raise quarter, but sustained execution questions linger, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Zimmer Biomet Holdings: Balancing Strong Segment Growth with US Knee Challenges – Hold Rating Maintained
- Cautious Outlook and Hold Recommendation for Zimmer Biomet Holdings Amid Volatility Concerns
- Zimmer Biomet Reports Strong Q2 2025 Results
- Zimmer Biomet Holdings: Hold Rating Maintained Amid Stable Growth and Second-Half Optimism
- Zimmer Biomet price target raised to $138 from $135 at Roth Capital